Experiences in implementing uHTS--cutting edge technology meets the real world

Area of Science:

• Drug discovery and development
• High-throughput screening (HTS) technologies
• Assay miniaturization

Background:

• Increasing corporate compound libraries necessitate efficient screening solutions.
• Advancements in assay technologies and screening platforms offer faster, high-density, low-volume screening.
• Cost reduction is a significant driver for adopting new HTS methodologies.

Purpose of the Study:

• To introduce Pfizer's adoption of cutting-edge HTS technology.
• To detail the implementation of 1-microliter screening using single molecule detection.
• To present the Mark-II EVOscreen platform developed in collaboration with Evotec.

Main Methods:

• Implementation of 1-microliter assay formats for high-throughput screening.
• Utilization of single molecule detection technology for enhanced sensitivity.
• Collaboration with Evotec OAI/Evotec Technologies for platform integration (Mark-II EVOscreen).

Main Results:

• Successful application of miniaturized HTS at Pfizer, Sandwich.
• Introduction of the Mark-II EVOscreen platform for advanced screening capabilities.
• Demonstration of the potential benefits and challenges of HTS miniaturization.

Conclusions:

• Miniaturized HTS, exemplified by Pfizer's 1-microliter approach, offers significant advantages in speed and cost-efficiency.
• The Mark-II EVOscreen platform represents a cutting-edge solution for modern drug discovery challenges.
• Careful consideration of potential pitfalls is essential for successful HTS miniaturization.